ResultsIQ › Latest results › Sai Parenterals Limited
Sai Parenterals Limited Q2 FY27 results deck summary
NSE: SAIPARENT · BSE: 544742
Results deck of 1 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue ₹196.1 cr and EBITDA ₹41.4 cr at a 21.1% margin, with FY27 revenue targeted at ₹750 cr and EBITDA margin at ~17%.
Key takeaways
- Q2 revenue Revenue from operations ₹196.1 cr (Q2 FY26: ₹54.9 cr, 257.4%; Q1 FY27: ₹179.9 cr, 9.0%), with Noumed consolidated for the full period.
- Gross margin Gross margin rose to 47.5% from 40.9% in Q1 FY27 on tighter inventory management and FIFO controls on a new ERP system.
- Noumed shift Noumed's move from distribution to manufacturing is expected to convert a ~10% distribution margin into manufacturing margin on the same revenue.
- Accreditation gap No injectable-export accreditation for the European Union exists at any facility today, with the new facility due July 2027.
Sai Parenterals Limited Q2 FY27 results
As filed: Revenue ₹195 cr, EBITDA ₹40.2 cr, PAT ₹10.5 cr, EBITDA margin 20.6%.
Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹195 cr). Scored once a year-earlier consolidated quarter exists.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹179 cr, EBITDA ₹23.5 cr, PAT ₹7.9 cr, EBITDA margin 13.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹179 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.9% in 30 days (Nifty 500: −3.1%).
- Q4 FY26: Revenue ₹198 cr, EBITDA ₹26.1 cr, PAT ₹13.2 cr, EBITDA margin 13.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹198 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +20.8% in 30 days (Nifty 500: +2.7%).
- Q3 FY26: Revenue ₹96.2 cr, EBITDA −₹3.6 cr, PAT −₹6.7 cr, EBITDA margin -3.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹96.2 cr). Scored once a year-earlier consolidated quarter exists.
Past price moves after results do not indicate future moves. Not a recommendation.
Sai Parenterals Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.